|
|
|
| Clinical value of 18F-FDG dual head coincidence imaging and 131I-SPECT/CT inthe diagnosis of patients with metastatic after resection of papillary thyroid carcinoma |
| SUN Yun-gang, FENG Hui-juan, LIU Jin-hua, HU Rui, OUYANG Wei |
| Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China |
|
|
|
|
Abstract Objective: The aim of this study was to evaluate the value of 18F-FDG dual head coincidence imaging and 131I-SPECT/CT in the diagnosis of patients with metastatic papillary thyroid carcinoma(PTC). Methods: Fifty-six patients who had thyroidectomy and radioiodine ablation of residual normal thyroid tissue were included. They all had 18F-FDG dual head coincidence imaging and 3 days after giving 3.7~7.4GBq 131I 131I-SPECT/CT were performed. We had comparative analysis of the two imaging results and the variable parameters between the 18F-FDG dual head coincidence imaging positive group and 18F-FDG dual head coincidence imaging negative group. Results: The sensitivity, specificity, accuracy, positive predictive value and negative predictive value were 84.21%(32/38), 94.44%(17/18), 87.5%(49/56), 96.97%(32/33), 73.91%(17/23). The difference was significant between 131I-SPECT/CT and 18F-FDG dual head coincidence imaging in sensitivity, accuracy, negative predictive value(χ2=16.114, 14.175, 6.285, all P<0.05）. Metastatic size of 18F-FDG dual head coincidence imaging positive group and negative group were (1.83±0.30)cm, (1.29±0.26)cm, respectively, the difference between them was statistically significant(P<0.001). Conclusion: 131I-SPECT/CT was likely to disclose more metastasis than 18F-FDG dual head coincidence imaging in patients with PTC. 18F-FDG dual head coincidence imaging is an important supplement of 131I-SPECT/CT in detecting metastatic PTC, the metastatic size affected the sensitivity of 18F-FDG dual head coincidence imaging.
|
|
Received: 02 March 2011
|
|
|
|
Corresponding Authors:
OUYANG Wei
|
|
|
|
|
|
|
2011, Vol. 22 
